Scott Kopetz, M.D., Ph.D.

Peer-Reviewed Articles

1. Deng, N, Duzagac, F, Bolivar, AM, Reyes-Uribe, L, Taggart, MW, Thirumurthi, S, Ricciardiello, L, Lynch, PM, You, YN, Kopetz, S, Scheet, PA, Lizee, GA, Reuben, A, Marin, F, Pineda, M, Sinha, K, Bansal, A, Capellá, G, Vilar Sanchez, E. Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signatures. Nature communications 17(1), 2026. e-Pub 2026. PMID: 41932865.
2. Folkert, I, Mehran, RJ, Sun, R, Morris, VK, Overman, MJ, Kee, BK, Antonoff, MB, Tzeng, CW, Dasari, NV, Cao, HT, Parseghian, C, Vilar Sanchez, E, Willis, JA, Newhook, TE, Hofstetter, WL, Kopetz, S, Vauthey, JN, Chun, YS. ASO Visual Abstract 33(10):8862-8863, 2026. e-Pub 2026. PMID: 42502090.
3. Vetere, G, Osterlund, E, Yousef, M, Payapwattanawong, S, Maddalena, G, Alshenaifi, J, Alfaro, KD, Knafl, M, Morris, VK, Parseghian, C, Raghav, KS, Wolff, RA, Dasari, NV, Overman, MJ, Kopetz, S, Shen, JY. Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer. Journal for immunotherapy of cancer 14(9), 2026. e-Pub 2026. PMID: 42686374.
4. Lei, M, Overman, MJ, Yao, J, Andre, T, Lonardi, S, Lenz, HJ, Aglietta, M, Gelsomino, F, Mcdermott, R, Wong, KM, Morse, MA, Van Cutsem, E, Hendlisz, A, Cardin, D, Neyns, B, Hill, A, Krishnamurthy, A, Chen, F, Kochuparambil, ST, Jenq, RR, Abdullaev, S, He, B, Novosiadly, R, Kopetz, S. Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer. Nature communications 16(1), 2025. e-Pub 2025. PMID: 41053075.
5. Lapelusa, M, Qiao, W, Iorgulescu, B, San Lucas, FA, Patel, KP, Bhamidipati, D, Thomas, J, You, YN, Foo, WC, Maru, D, Thirumurthi, S, Morris, VK, Kopetz, S, Overman, MJ, Ludford, K. Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40374594.
6. Maddalena, G, Zeineddine, F, Chowdhury, S, Zeineddine, MA, Yousef, A, Bergamo, F, Lonardi, S, Yap, TA, White, MG, Overman, MJ, Kopetz, S, Shen, JY. Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants. Journal for immunotherapy of cancer 13(11), 2025. e-Pub 2025. PMID: 41253491.
7. Odisio, BC, Albuquerque, J, Lin, YM, Anderson, BM, OConnor, C, Rigaud, B, Briones-Dimayuga, M, Jones, AK, Fellman, B, Huang, SY, Kuban, JD, Metwalli, ZA, Sheth, RA, Habibollahi, P, Patel, MN, Shah, KY, Cox, V, Kang, HC, Morris, VK, Kopetz, S, Javle, M, Kaseb, A, Tzeng, CW, Cao, HT, Newhook, TE, Chun, YS, Vauthey, JN, Gupta, S, Paolucci, I, Brock, K. Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL). The Lancet Gastroenterology and Hepatology 10(5):442-451, 2025. e-Pub 2025. PMID: 40090348.
8. Yaeger R, Uboha NV, Pelster MS, Bekaii-Saab TS, Barve M, Saltzman J, Sabari JK, Peguero JA, Paulson AS, Jänne PA, Cruz-Correa M, Anderes K, Velastegui K, Yan X, Der-Torossian H, Klempner SJ, Kopetz SE. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discov 14(6):982-993, 2024. e-Pub 2024. PMID: 38587856.
9. Xiang, K, Wang, E, Mantyh, J, Rupprecht, G, Negrete, M, Sanati, G, Hsu, C, Randon, PM, Dohlman, AB, Kretzschmar, K, Bose, S, Giroux, N, Ding, S, Wang, L, Balcazar, JP, Huang, Q, Sundaramoorthy, P, Xi, R, McCall, S, Wang, Z, Jiang, C, Kang, Y, Kopetz, S, Crawford, G, Lipkin, SM, Wang, XF, Clevers, H, Hsu, D, Shen, X. Chromatin Remodeling in Patient-Derived Colorectal Cancer Models. Advanced Science 11(16), 2024. e-Pub 2024. PMID: 38380561.
10. Amaria, RN, Knisely, A, Vining, D, Kopetz, S, Overman, MJ, Javle, M, Antonoff, MB, Tzeng, CD, Wolff, RA, Pant, S, Lito, K, Rangel, KM, Fellman, B, Yuan, Y, Lu, KH, Sakellariou-Thompson, D, Haymaker, CL, Forget, MA, Hwu, P, Bernatchez, C, Jazaeri, AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. Journal for immunotherapy of cancer 12(2), 2024. e-Pub 2024. PMID: 38309721.
11. Raghav KPS, Loree JM, Kopetz S. PRESSING need of precision care in HER2-positive CRC: The ELEPHANT in the room. Clinical Cancer Research 30(2):260-262, 2024. e-Pub 2024. PMID: 37975903.
12. Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nature medicine 30(1):265-270, 2024. e-Pub 2024. PMID: 38177853.
13. Zheng C, Wei Y, Zhang P, Lin K, He D, Teng H, Manyam G, Zhang Z, Liu W, Lee HRL, Tang X, He W, Islam N, Jain A, Chiu Y, Cao S, Diao Y, Meyer-Gauen S, Höök M, Malovannaya A, Li W, Hu M, Wang W, Xu H, Kopetz S, Chen Y. CRISPR-Cas9-based functional interrogation of unconventional translatome reveals human cancer dependency on cryptic non-canonical open reading frames. Nature Structural and Molecular Biology 30(12):1878-1892, 2023. e-Pub 2023. PMID: 37932451.
14. Zhang X, Irajizad E, Hoffman KL, Fahrmann JF, Li F, Seo YD, Browman GJ, Dennison JB, Vykoukal J, Luna PN, Siu W, Wu R, Murage E, Ajami NJ, McQuade JL, Wargo JA, Long JP, Do KA, Lampe JW, Basen-Engquist KM, Okhuysen PC, Kopetz S, Hanash SM, Petrosino JF, Scheet P, Daniel CR. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. EBioMedicine 98:104873, 2023. e-Pub 2023. PMID: 38040541.
15. Napolitano S, Woods M, Lee HM, De Falco V, Martini G, Della Corte CM, Martinelli E, Famiglietti V, Ciardiello D, Anderson A, Fowlkes NW, Villareal OE, Sorokin A, Kanikarla P, Coker O, Morris V, Altucci L, Tabernero J, Troiani T, Ciardiello F, Kopetz S. Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. Clinical Cancer Research 29(12):2299-2309, 2023. e-Pub 2023. PMID: 37040395.
16. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. Journal of Clinical Oncology 41(12):2181-2190, 2023. e-Pub 2023. PMID: 36623241.
17. Raghav K, Ou FS, Venook AP, Innocenti F, Sun R, Lenz HJ, Kopetz S. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). Journal of Clinical Oncology 41(3):472-478, 2023. e-Pub 2023. PMID: 36067452.
18. Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. Journal of Clinical Oncology 41(3):460-471, 2023. e-Pub 2023. PMID: 36351210.
19. Eluri M, Kopetz S, Parseghian CM. Truncal dynamics may trump: serial ctDNA to predict early therapeutic response. Clinical Cancer Research 29(2):OF1-OF10, 2023. e-Pub 2023. PMID: 36378102.
20. Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. Journal of Hematology and Oncology 15(1):23, 2022. e-Pub 2022. PMID: 35260176.
21. Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nature Biotechnology 40(11):1624-1633, 2022. e-Pub 2022. PMID: 35697807.
22. Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G, Kwong LN, Johnson B, Morris VK, Jones P, Menter DG, Lee MS, Kopetz S. Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6. Cancer Res 82(18):3335-3344, 2022. e-Pub 2022. PMID: 35913398.
23. Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer 10(8), 2022. e-Pub 2022. PMID: 36007963.
24. Ding S, Hsu C, Wang Z, Natesh NR, Millen R, Negrete M, Giroux N, Rivera GO, Dohlman A, Bose S, Rotstein T, Spiller K, Yeung A, Sun Z, Jiang C, Xi R, Wilkin B, Randon PM, Williamson I, Nelson DA, Delubac D, Oh S, Rupprecht G, Isaacs J, Jia J, Chen C, Shen JP, Kopetz S, McCall S, Smith A, Gjorevski N, Walz AC, Antonia S, Marrer-Berger E, Clevers H, Hsu D, Shen X. Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell 29(6):905-917.e6, 2022. e-Pub 2022. PMID: 35508177.
25. Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilie PG, Yap TA, Kopetz S, Sander C, Korkut A. Precision combination therapies based on recurrent oncogenic co-alterations. Cancer Discov 12(6):1542-1559, 2022. e-Pub 2022. PMID: 35412613.
26. Orouji E, Raman AT, Singh AK, Sorokin A, Arslan E, Ghosh AK, Schulz J, Terranova C, Jiang S, Tang M, Maitituoheti M, Callahan SC, Barrodia P, Tomczak K, Jiang Y, Jiang Z, Davis JS, Ghosh S, Lee HM, Reyes-Uribe L, Chang K, Liu Y, Chen H, Azhdarinia A, Morris J, Vilar E, Carmon KS, Kopetz SE, Rai K. Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. Gut 71(5):938-949, 2022. e-Pub 2022. PMID: 34059508.
27. Hu, J, Yang, Q, Zhang, W, Du, H, Chen, Y, Zhao, Q, Dao, L, Xia, X, Fowlkes, NW, Zhang, Z, Mahadeo, KM, Gorlick, R, Kopetz, S, Dotti, G, Li, S. Cell membrane-Anchored and tumor-Targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. Journal for immunotherapy of cancer 10(1), 2022. e-Pub 2022. PMID: 35027427.
28. Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 23(1):115-124, 2022. e-Pub 2022. PMID: 34919824.
29. Sun, H, Cao, S, Mashl, RJ, Mo, CK, Zaccaria, S, Wendl, MC, Davies, S, Bailey, MH, Primeau, T, Hoog, J, Mudd, JL, Dean, DA, Patidar, R, Chen, L, Wyczalkowski, MA, Jayasinghe, R, Rodrigues, FM, Terekhanova, NV, Li, Y, Lim, KH, Wang-Gillam, A, Van Tine, BA, Ma, C, Aft, R, Fuh, KC, Schwarz, JK, Roth, JA, Akcakanat, A, Chen, H, Dai, B, Gibbons, DL, Ha, MJ, Jensen, VB, Kim, M, Kopetz, S, Menter, DG, Meraz, I, Sorokin, A, Tapia, C, Wang, J, Westin, SN, Xi, Y, Yang, F, Yap, TA, Yennu Nanda, VG, Zhang, X, Zheng, X, Davies, MA, Fang, B, Meric-Bernstam, F. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nature communications 12(1), 2021. e-Pub 2021. PMID: 34429404.
30. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
31. Kopetz S, Bent A. Going With the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays. Clin Cancer Res 27(20):5449-5451, 2021. e-Pub 2021. PMID: 34389607.
32. Wang L, Wang E, Prado Balcazar J, Wu Z, Xiang K, Wang Y, Huang Q, Negrete M, Chen KY, Li W, Fu Y, Dohlman A, Mines R, Zhang L, Kobayashi Y, Chen T, Shi G, Shen JP, Kopetz S, Tata PR, Moreno V, Gersbach C, Crawford G, Hsu D, Huang E, Bu P, Shen X. Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 Axis. Adv Sci (Weinh) 8(19):e2004673, 2021. e-Pub 2021. PMID: 34378358.
33. Loree JM, Wang Y, Syed MA, Sorokin AV, Coker O, Xiu J, Weinberg BA, VanderWalde AM, Tesfaye A, Raymond VM, Miron B, Tarcic G, Zelichov O, Broaddus RR, Ng PKS, Jeong KJ, Tsang YH, Mills GB, Overman MJ, Grothey A, Marshall JL, Kopetz S. Clinical and functional characterization of atypical KRAS/NRAS mutations in metastatic colorectal cancer. Clin Cancer Res 27(16):4587-4598, 2021. e-Pub 2021. PMID: 34117033.
34. Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology 161(1):196-210, 2021. e-Pub 2021. PMID: 33745946.
35. Cleary JM, Wang V, Heist RS, Kopetz ES, Mitchell EP, Zwiebel JA, Kapner KS, Chen HX, Li S, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Meric-Bernstam F, Dillmon MS, Williams PM, Hamilton SR, Conley BA, Aguirre AJ, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clin Cancer Res 27(11):2996-3004, 2021. e-Pub 2021. PMID: 33637626.
36. Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
37. Zhao M, Scott S, Evans KW, Yuca E, Saridogan T, Zheng X, Wang H, Korkut A, Cruz Pico CX, Demirhan ME, Kirby B, Kopetz S, Diala I, Lalani AS, Piha-Paul S, Meric-Bernstam F. Combining neratinib with CDK4/6, mTOR and MEK inhibitors in models of HER2-positive cancer. Clin Cancer Res 27(6):1681-1694, 2021. e-Pub 2021. PMID: 33414137.
38. Mehrvarz Sarshekeh A, Alshenaifi J, Roszik J, Manyam G, Advani SM, Katkhuda R, Verma A, Lam M, Willis JA, Shen JP, Morris JS, Davis JS, Loree JM, Lee HM, Ajani JA, Maru DM, Overman MJ, Kopetz S. ARID1A mutation may define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer. Clin Cancer Res 27(6):1663-1670, 2021. e-Pub 2021. PMID: 33414133.
39. Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406) 39(4):285-294, 2021. e-Pub 2021. PMID: 33356422.
40. Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol 39(4):273-284, 2021. e-Pub 2021. PMID: 33503393.
41. Chen B, Dragomir MP, Fabris L, Bayraktar R, Knutsen E, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, Cruz De Los Santos M, Anfossi S, Shimizu M, Shah MY, Ling H, Shen P, Multani AS, Pardini B, Burks JK, Katayama H, Reineke LC, Huo L, Syed M, Song S, Ferracin M, Oki E, Fromm B, Ivan C, Bhuvaneshwar K, Gusev Y, Mimori K, Menter D, Sen S, Matsuyama T, Uetake H, Vasilescu C, Kopetz S, Parker-Thornburg J, Taguchi A, Hanash SM, Girnita L, Slaby O, Goel A, Varani G, Gagea M, Li C, Ajani JA, Calin GA. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology 159(6):2146-2162.e33, 2020. e-Pub 2020. PMID: 32805281.
42. Kawaguchi Y, Kopetz S, Lillemoe HA, Hwang H, Wang X, Tzeng CD, Chun YS, Aloia TA, Vauthey JN. A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status. J Natl Compr Canc Netw 18(11):1500-1508, 2020. e-Pub 2020. PMID: 33152698.
43. Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C, Lizée G. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun 11(1):5332, 2020. e-Pub 2020. PMID: 33087697.
44. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. e-Pub 2020. PMID: 32632268.
45. McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin SY. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell 37(3):371-386.e12, 2020. e-Pub 2020. PMID: 32109374.
46. Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med 26(1):39-46, 2020. e-Pub 2020. PMID: 31873309.
47. Burke HB, Kopetz S. Is the Patient Cured?. JAMA Oncol. e-Pub 2019. PMID: 31621795.
48. Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A. How liquid biopsies can change clinical practice in oncology. Ann Oncol 30(10):1580-1590, 2019. e-Pub 2019. PMID: 31373349.
49. Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol:e191870. e-Pub 2019. PMID: 31415071.
50. Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. J Clin Oncol 37(17):1460-1469, 2019. e-Pub 2019. PMID: 30892987.
51. Morris V, Dasari A, Kopetz S. Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?. JAMA Oncol. e-Pub 2019. PMID: 31070713.
52. Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA, DePinho RA. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell 35(4):559-572.e7, 2019. e-Pub 2019. PMID: 30905761.
53. Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer 7(1):37, 2019. e-Pub 2019. PMID: 30736857.
54. Kopetz S. New therapies and insights into the changing landscape of colorectal cancer. Nat Rev Gastroenterol Hepatol 16(2):79-80, 2019. e-Pub 2019. PMID: 30575801.
55. Zacharias NM, Ornelas A, Lee J, Hu J, Davis J, Uddin MN, Pudakalakatti S, Menter D, Karam JA, Wood CG, Hawk E, Kopetz S, Vilar E, Bhattacharya P, Millward S. Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angew Chem Int Ed Engl. e-Pub 2019. PMID: 30680862.
56. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-challenge. Ann Oncol. e-Pub 2018. PMID: 30462160.
57. Dasari A, Grothey A, Kopetz S. Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. J Clin Oncol:JCO2018789032. e-Pub 2018. PMID: 30376428.
58. Jung YS, Jun S, Kim MJ, Lee SH, Suh HN, Lien EM, Jung HY, Lee S, Zhang J, Yang JI, Ji H, Wu JY, Wang W, Miller RK, Chen J, McCrea PD, Kopetz S, Park JI. TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/β-catenin signalling. Nat Cell Biol. e-Pub 2018. PMID: 30374053.
59. Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol 4(8):1085-1092, 2018. e-Pub 2018. PMID: 29710228.
60. Lin SH, Raju GS, Huff C, Ye Y, Gu J, Chen JS, Hildebrandt MAT, Liang H, Menter DG, Morris J, Hawk E, Stroehlein JR, Futreal A, Kopetz S, Mishra L, Wu X. The somatic mutation landscape of premalignant colorectal adenoma. Gut 67(7):1299-1305, 2018. e-Pub 2018. PMID: 28607096.
61. Liu L, Toung JM, Jassowicz AF, Vijayaraghavan R, Kang H, Zhang R, Kruglyak KM, Huang HJ, Hinoue T, Shen H, Salathia NS, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Bibikova M, Granger G, Barnes B, Shen R, Gutekunst K, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder SL, Kopetz ES, Amaria RN, Meric-Bernstam F, Laird PW, Fan JB, Janku F. Targeted Methylation Sequencing of Plasma Cell-free DNA for Cancer Detection and Classification. Ann Oncol 29(6):1445-1453, 2018. e-Pub 2018. PMID: 29635542.
62. Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, Eng C, Maru DM, Ychou M, Vauthey JN, Loyer EM, Kopetz S. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut 67(6):1095-1102, 2018. e-Pub 2018. PMID: 29084828.
63. Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. JAMA Oncol 4(4):e175245, 2018. e-Pub 2018. PMID: 29423521.
64. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 36(8):773-779, 2018. e-Pub 2018. PMID: 29355075.
65. Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S. Genomic landscape of cell-free DNA in patients with colorectal cancer. Cancer Discov 8(2):164-173, 2018. e-Pub 2018. PMID: 29196463.
66. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29(1):44-70, 2018. e-Pub 2018. PMID: 29155929.
67. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 29(1):139-144, 2018. e-Pub 2018. PMID: 29069279.
68. Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun 8(1):1050, 2017. e-Pub 2017. PMID: 29051489.
69. Lee WC, Kopetz S, Wistuba II, Zhang J. Metastasis of cancer: when and how?. Ann Oncol 28(9):2045-2047, 2017. e-Pub 2017. PMID: 28911075.
70. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. e-Pub 2017. PMID: 28734759.
71. Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P, Kopetz S, Messick C, Skibber JM, Chang GJ. Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. J Clin Oncol:JCO2016721464. e-Pub 2017. PMID: 28657814.
72. Sundar R, Hong DS, Kopetz S, Yap TA. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discov 7(6):558-560, 2017. e-Pub 2017. PMID: 28576843.
73. Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol:JCO2016714394. e-Pub 2017. PMID: 28486044.
74. Loree JM, Kopetz S. Why a One Size Fits All Approach to RAS Might Not Fit Colorectal Cancer. J Natl Compr Canc Netw 15(4):545-547, 2017. e-Pub 2017. PMID: 28404763.
75. Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 Mutation Testing of Unamplified Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using Droplet Digital Polymerase Chain Reaction. Ann Oncol. e-Pub 2016. PMID: 27993791.
76. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol. e-Pub 2016. PMID: 27045102.
77. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey A, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol. e-Pub 2016. PMID: 26787237.
78. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol 33(34):4032-8, 2015. e-Pub 2015. PMID: 26460303.
79. Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, Fang YF, Lee HJ, Lee HH, Tai SK, Yang MH, Morelli MP, Sen M, Ladbury JE, Chen CH, Grandis JR, Kopetz S, Hung MC. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest. e-Pub 2015. PMID: 26571401.
80. Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev 41(8):653-9, 2015. e-Pub 2015. PMID: 26220150.
81. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol 33(25):2753-62, 2015. e-Pub 2015. PMID: 26014291.
82. Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
83. Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: Refining the Patient Population. J Clin Oncol 33(7):682-5, 2015. e-Pub 2015. PMID: 25584005.
84. Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock MD, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, Hoefler G, Almeida MI, Hsiao A, Zhang X, Primrose JN, Packham GK, Liu K, Bojja K, Gafà R, Xiao L, Rossi S, Song JH, Vannini I, Fanini F, Kopetz S, Zweidler-McKay P, Wang X, Ionescu C, Irimie A, Fabbri M, Lanza G, Hamilton SR, Berindan-Neagoe I, Medico E, Mirnezami AH, Calin GA, Nicoloso MS. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut. e-Pub 2015. PMID: 25804630.
85. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer. Ann Oncol 25(10):2008-14, 2014. e-Pub 2014. PMID: 25009008.
86. Overman MJ, Modak J, Kopetz ES, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?. J Clin Oncol 31(1):17-22, 2013. e-Pub 2013. PMID: 23129736.
87. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases. J Clin Oncol 30(36):4566-72, 2012. e-Pub 2012. PMID: 23150701.
88. Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 61(9):1291-8, 2012. e-Pub 2012. PMID: 21997556.
89. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 72(3):779-89, 2012. e-Pub 2012. PMID: 22180495.
90. Brouquet A, Abdalla EK, Kopetz ES, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29(8):1083-90, 2011. e-Pub 2011. PMID: 21263087.
91. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. J Clin Oncol 28(15):2549-2555, 2010. e-Pub 2010. PMID: 20406923.
92. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 28(3):453-9, 2010. e-Pub 2010. PMID: 20008624.
93. Kopetz S, Chang G, Overman M, Eng C, Larson DW, Grothey A, Vauthey JN, Sargent D, McWilliams R. Improved Survival in Metastatic Colorectal Cancer is Associated with Sequential Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 2009. e-Pub 2009. PMID: 19470929.
94. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 26(15S):4538, 2009. e-Pub 2009. PMID: 19164203.
95. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842-9, 2009. e-Pub 2009. PMID: 19383922.
96. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S. Individualized Therapies in Colorectal Cancer: KRAS as a Marker for Response to EGFR-targeted Therapy (Invited Editorial). J Hematol Oncol 2(18):18, 2009. e-Pub 2009. PMID: 19386128.
97. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway. J Clin Oncol 26(12):2000-5, 2008. e-Pub 2008. PMID: 18421052.

Review Articles

1. Singh M, Morris VK, Bandey IN, Hong DS, Kopetz S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer 10(7):598-609, 2024. e-Pub 2024. PMID: 38821852.
2. Villarreal OE, Kopetz S. EMP1+ tumor cells drive metastatic relapse. Cell research 33(5):337-338, 2023. e-Pub 2023. PMID: 36646758.
3. Bose S, Barroso M, Chheda MG, Clevers H, Elez E, Kaochar S, Kopetz SE, Li XN, Meric-Bernstam F, Meyer CA, Mou H, Naegle KM, Pera MF, Perova Z, Politi KA, Raphael BJ, Robson P, Sears RC, Tabernero J, Tuveson DA, Welm AL, Welm BE, Willey CD, Salnikow K, Chuang JH, Shen X. A path to translation: How 3D patient tumor avatars enable next generation precision oncology. Cancer Cell 40(12):1448-1453, 2022. e-Pub 2022. PMID: 36270276.
4. Morris VK, Kopetz S. Don't blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic. Nat Rev Cancer 22(6):317-318, 2022. e-Pub 2022. PMID: 35277674.
5. Wan JCM, Mughal TI, Razavi P, Dawson SJ, Moss EL, Govindan R, Tan IB, Yap YS, Robinson WA, Morris CD, Besse B, Bardelli A, Tie J, Kopetz S, Rosenfeld N. Liquid biopsies for residual disease and recurrence. Med (N Y) 2(12):1292-1313, 2021. e-Pub 2021. PMID: 35590147.
6. Dragomir MP, Kopetz S, Ajani JA, Calin GA. Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. Gut 69(4):748-763, 2020. e-Pub 2020. PMID: 32034004.
7. Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol. e-Pub 2019. PMID: 31289352.
8. Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D. Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev 66:95-103, 2018. e-Pub 2018. PMID: 29730462.
9. Lee MS, Menter DG, Kopetz S. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. J Natl Compr Canc Netw 15(3):411-419, 2017. e-Pub 2017. PMID: 28275039.
10. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 17(2):79-92, 2017. e-Pub 2017. PMID: 28050011.
11. Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S. Circulating Tumor Markers: Harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol. e-Pub 2016. PMID: 27998963.

Professional Educational Materials

1. Kopetz ES. Etiology and Management of Bowel Perforation in Patients with Colorectal Cancer” Gastrointestinal Malignancies: Putting Theory Into Practice at M. D. Anderson. M. D. Anderson, 2007.

Editorials

1. Morelli MP, Kopetz S. Hurdles and complexities of codon 13 KRAS mutations. J Clin Oncol 30(29):3565-7, 2012. PMID: 22927534.
2. Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men 18(19):5160-2, 2012. PMID: 22912394.
3. Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet 371(9617):963-5, 2008. PMID: 18358910.

Abstracts

1. Osterlund E, Vetere G, Payapwattanawong S, Alfaro K, Parseghian C, Overman MJ, Shen X, YC Shen JP, Van K Morris II, Singh Raghav KP, Dasari A, Kopetz S. Minimal residual disease (MRD) trials in colorectal cancer (CRC): An overview of a heterogeneous field. 2026 ASCO Gastrointestinal Cancers Symposium 44(2), 2026. e-Pub 2026.
2. Takeda M, Yang Z, Theardy MS, Sorokin A, Coker O, Chen S, Vien LT, Bover L, Ying H, Kopetz S, Yao W. Syndecan 1 is a therapeutic target for KRAS-driven pancreatic cancer. AACR Annual Meeting 2024 84(17), 2024. e-Pub 2024.
3. Singh Raghav KP, Xiao L, Lewis C, Zeller BE, Overman MJ, Huey RW, Dasari A, Chang K, Quinn K, YC Shen JP, Parseghian CM, Willis J, Ludford K, Van K Morris II, Wolff RA, Wang XS, Drusbosky L, Kopetz S. A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D. 2024 ASCO Annual Meeting 42(17), 2024. e-Pub 2024.
4. Kopetz S, Boni V, Kato K, Raghav K, Pallis A, Habermehl C, Galipelli S, Courlet P, Rivera I. First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC). 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
5. Pellatt AJ, Maddalena G, Bent AH, Parseghian CM, Huey RW, Singh Raghav KP, Van K Morris II, Overman MJ, Morelli MP, Willis J, Le P, YC Shen JP, Alfaro K, Aziz K, Kell RJ, Sun R, Kopetz S, Dasari A. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort: Results from the MD Anderson INTERCEPT program. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
6. Wainberg ZA, Han S, Lee S, Lee K, Kopetz S, Mizrahi J, Hong YS, Ghiringhelli F, Italiano A, Tougeron D, Beagle B, Boakye M, Zhao T, Rhee J, A Nuyten DS, Cecchini M. ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC). 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
7. LaPelusa MB, San Lucas FA, Iorgulescu B, Patel KP, You Y, Foo WC, Maru DM, Kopetz S, Ludford K, Van K Morris II, Overman MJ. Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
8. Parikh AR, Chiorean E, Atreya CE, Zheng L, Kopetz S, Spira AI, Spigel DR, Cui Y, Osgood R, Tran R, Morris SR, Ulahannan SV. Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
9. Loree JM, Dasari A, Willis J, Gothwal H, Shaheed M, Singh K, Shaheed H, Mangal R, Gothwal S, Pant A, Overman MJ, Kopetz S, Singh Raghav KP. Racial/ethnic representation and disparities in preclinical cancer models. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
10. Eluri M, Sun R, Bubie A, Alshenaifi J, Zhang N, Drusbosky L, Parseghian CM, Singh Raghav KP, Kopetz S. Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
11. Bahrambeigi V, Lee JJ, Branchi V, Rajapakshe KI, Xu Z, Kui N, Henry JT, Kun W, Stephens BM, Dhebat S, Hurd MW, Sun R, Yang P, Ruppin E, Wang W, Kopetz S, Maitra A, Guerrero PA. Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-Specific Transcriptome and Molecular Subtype. AACR Annual Meeting 2024 84(10):1719–1732, 2024. e-Pub 2024.
12. Hornstein NJ, Wang M, Yousef A, Chowdhury S, Zeineddine F, Zeineddine M, Yousef M, You S, Gunes B, Menter D, Kopetz S, Shen JP. Cell-type-specific gene programs suggest immune and stromal drivers of relapse in colorectal cancer. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
13. Lee HM, Saw AK, Morris VK, Singh AK, Napolitano S, Sorokin A, Marie PK, Coker O, Villarreal OE, Anvar NE, Rai K, Kopetz S. Elevated H3K27 trimethylation mediates adaptation to DNA demethylation in BRAFV600E-mutated colorectal cancer. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
14. Villarreal OE, Xiao L, Allam J, Sorokin A, Yuan Y, Kopetz S, Raghav KP. Clinical efficacy and safety of HER2 targeted therapy in patients with metastatic colorectal cancer: A systematic review and meta-analysis. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
15. Mohamed AM, Cho KS, Soeung M, Anderson A, Alshenaifi J, Manyam G, Villareal O, Davis J, Norton W, Gao S, Bristow C, Carbone F, Napolitano S, Coker O, Khanduri I, Huang J, Maru DM, Pilato MD, Sun R, Wang L, Menter DG, Genovese G, Draetta G, Fowlkes N, Kopetz S. Anti-CSF1R antibody monotherapy inhibits minimal residual disease in a novel immunocompetent murine colorectal cancer metastasis model. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
16. Loree JM, Dasari A, Shaheed M, Gothwal H, Singh K, Shaheed H, Mangal R, Gothwal S, Willis J, Overman MJ, Kopetz S, Singh Raghav KP. Racial and ethnic representation and disparities on clinical guideline panels in oncology. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
17. Villarreal OE, Lee HM, Tran H, Machado A, Alshenaifi J, Wong CW, Coker O, Minelli R, Peoples M, Martinez AH, Fowlkes N, Kanikarla P, Lin K, Bristow C, Viale A, Marszalek JR, Shen JP, Kopetz S. ASCL2+ tumor cells modulate the response of colorectal cancer to MAPK targeting therapy. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
18. Chu Y, Cho KS, Khanduri I, Zhou T, Jiang J, Liu Y, Yan X, Pei G, Dai Y, Liu Y, Wang R, Jadhav AS, Hernandez S, Kadara H, Solis Soto LM, Kopetz S, Maru DM, Wang L. SpatialCS: A tool to effectively integrate histological annotations and spatial transcriptomics analysis. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
19. Cho KS, Jiang J, Zhang D, Liu Y, Chen J, Segura RL, Yan X, Pei G, Soto LM, Chu Y, Sinjab AF, Yee C, Kopetz S, Maitra A, Futreal A, Lazar A, Jazaeri AA, Kadara H, Gao J, Li M, Wang L. iStarTLS: Advanced detection and phenotyping of tertiary lymphoid structures. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
20. Ridinger M, Marie PK, Gao F, Liu Z, Maddalena G, Menter D, Sorokin A, Smeal T, Kopetz S. The PLK1 inhibitor, onvansertib, is active as monotherapy and in combination with cetuximab in RAS wild-type colorectal cancer patient-derived xenografts. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
21. Coker O, Sorokin A, Akhave N, Pan K, Gao F, Liu Z, Kanikarla P, Lee H, Villarreal O, Alshenaifi J, Maddalena G, Mohamed A, Prescod D, Menter D, Chowdury S, Corcoran R, Rai K, Hong D, Kopetz S. YAP-TAZ-TEAD transcriptional program is a prominent driver of acquired resistance to KRASG12C-based therapies in patients with metastatic colorectal cancer. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
22. der Pol YV, Yilma B, Morris VK, Chao C, Harris M, Guinney J, Kopetz S. Molecular characterization of microsatellite stable (MSS) colorectal cancer (CRC) patients with a BRAF V600E mutation. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
23. Whitehead CE, Ziemke EK, Frankowski-McGregor CL, Mumby RA, Chung J, Li J, Osher N, Coker O, Norris M, Kopetz S, Baladandayuthapani V, Hollingshead M, Verma S, Sebolt-Leopold JS. MTX-531, a first-in-class pan-PI3K inhibitor spares hyperinsulinemia yielding durable tumor regressions and resilience to adaptive resistance. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
24. Peng DH, Tedeschi A, Herdeis L, Schaaf O, Savarese F, Rocchetti F, Popow J, Huber HJ, Wilding B, Treu M, Fuchs J, Bröeker J, Wunberg T, Schischlik F, Lipp J, Williams M, Chandler V, Deckard CE, Ramamoorthy V, Daniele JR, Kopetz S, Kim M, Gibbons DL, Vellano CP, Marszalek JR, Heffernan TP, McConnell D, Pearson M, Kraut N, Rudolph D. KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRASG12V-driven preclinical models. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
25. Negrao MV, Molkentine D, Paula AG, Hover L, Nilsson M, Vokes N, Engstrom L, Calinisan A, Waters L, Briere DM, Hallin J, Blumenschein GR, Skoulidis F, Kopetz SE, Hong DS, Gibbons DL, Olson P, Christensen J, Heymach JV. Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
26. Chowdhury S, Ahmed J, Haridas V, Hong DS, Kopetz S, Shen JP. Activating PIK3CA mutations and hedgehog signaling may confer resistance to KRAS inhibition in colorectal cancer. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
27. Johnson CW, Terrell EM, Cook J, Shui B, O'Donoghue E, Hull S, Yang MH, Sheth S, Yaeger R, Kopetz S, Morrison DK, Haigis K. Ala59 mutants of KRAS cooperate with Nf1 loss to enhance colon tumorigenesis. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
28. Higbie V, Shah P, Bent AH, Dasari A, Huey RW, Johnson B, Kee BK, Kopetz S, Lee MS, Ludford K, Morelli MP, Morris VK, Parseghian CM, Singh Raghav KP, YC Shen JP, Willis J, Wolff RA, Overman MJ. Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade: A single center retrospective analysis. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
29. Bhutiani N, Johnson B, Kopetz S, White M, Willis J, Morris VK, Chang GJ, Uppal A. Immune checkpoint blockade combined with targeted therapies to provide disease control in mismatch repair-proficient colorectal cancer with peritoneal metastases. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
30. Maddalena G, der Pol YV, Rivers Z, Dasari A, Rogers JE, Guinney J, Kopetz S, Singh Raghav KP. Impact of KRAS codon-specific mutations on survival of patients with metastatic CRC (mCRC) treated with trifluridine-tipiracil (TAS) plus bevacizumab (Bev): A real-world analysis. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
31. Van K Morris II, Guthrie KA, Kopetz S, Breakstone R, Karasic TB, Hu ZI, Colby S, Fakih M, Gholami S, Gold PJ, Chiorean E, Philip PA. SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer. 2024 ASCO Annual Meeting 42(3), 2024. e-Pub 2024.
32. Loree JM, Bubie A, Eluri M, Parseghian CM, Overman MJ, Zhang N, Drusbosky L, Kopetz S, Singh Raghav KP. Clinical utility of serial circulating tumor DNA (ctDNA) to identify acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC). 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
33. Parseghian CM, Lee JK, Quintanilha J, Schrock AB, Graf R, Pasquina L, Sivakumar S, Oxnard GR, Tukachinsky H, Klempner SJ, Kopetz S. Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC). 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
34. Dasari A, Yu G, Kopetz S, Puhalla SL, Lucas PC, Halil Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree JM, Wolmark N, Yothers G, George TJ, Lieu CH. Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008. 2024 ASCO Annual Meeting 42(3), 2024. e-Pub 2024.
35. White M, Damania A, Alshenaifi J, Sahasrabhojane P, Peacock O, Losh J, Wong MC, Berkova Z, Nguyen ST, Chang GJ, Wargo JA, Ajami NJ, Kopetz S, You Y. Tumoral microbial and pathway alterations associated with young-onset rectal cancer and its response to therapy. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
36. Yousef MM, Yousef AM, Fanaeian MM, Chowdhury S, Knafl M, Zeineddine M, Alfaro K, Uppal A, Sun R, Wang W, Singh Raghav KP, Willis J, Kopetz S, YC Shen JP. Understanding causes of racial/ethnic survival disparity in 47,178 patients with colorectal cancer: A quantitative evaluation of molecular, socioeconomic, and clinical covariates. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
37. Lieu CH, Yu G, Kopetz S, Puhalla SL, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree JM, Wolmark N, Yothers G, George TJ, Dasari A. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA). 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
38. Overman MJ, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Blanke CD, Hong TS, Wolmark N, Hochster HS, George TJ, Rocha Lima CMSP. Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
39. Uppal A, Bhutiani N, YC Shen JP, Alfaro K, Kell RJ, Yousef MM, Yousef AM, Konishi T, Holliday E, Morris VK, Dasari A, Willis J, Newhook TE, Bednarski BK, You Y, Peacock O, Messick C, Das P, Chang GJ, Kopetz S. Association of pathologic nodal status with minimal residual disease after neoadjuvant treatment and resection of locally advanced rectal cancer. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
40. Kasi PM, Rivero S, Aushev VN, Langer N, Wang CG, Cannon TL, Berim LD, Feinstein T, Grothey A, McCollom JW, Kalmadi SR, Zakari A, Dayyani F, Gravenor D, Meyer JM, Sharif S, Jurdi AA, Liu MC, Aleshin A, Kopetz S. Patient-reported outcomes from the BESPOKE CRC study. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
41. Kasi PM, Aushev VN, Ensor J, Langer N, Wang CG, Cannon TL, Berim LD, Feinstein T, Grothey A, McCollom JW, Kalmadi SR, Zakari A, Dayyani F, Gravenor D, Meyer JM, Sharif S, Jurdi AA, Liu MC, Aleshin A, Kopetz S. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
42. Pellatt AJ, Maddalena G, Eluri M, Parseghian CM, Aziz K, Alfaro K, Kell RJ, Bent AH, Huey RW, Uppal A, Konishi T, Overman MJ, Morelli MP, Willis J, YC Shen JP, Singh Raghav KP, Newhook TE, Morris VK, Dasari A, Kopetz S. Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease: Results from the MD Anderson INTERCEPT Program. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
43. Maddalena G, Pellatt AJ, Eluri M, Parseghian CM, Aziz K, Alfaro K, Kell RJ, Bent AH, Huey RW, Uppal A, Konishi T, Overman MJ, Morelli MP, Willis J, YC Shen JP, Singh Raghav KP, Newhook TE, Morris VK, Dasari A, Kopetz S. INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
44. Takeda M, Sorokin A, Theardy M, Coker O, Kopetz S, Ying H, Draetta G, DePinho RA, Yao W. Targeting Syndecan1 to overcome acquired resistant to KRAS inhibitor in gastrointestinal cancer. AACR 84(2), 2024.
45. Kopetz S, Yoshino T, Kim TW, Wasan HS, Cutsem EV, Ciardiello F, Maughan TS, Eng C, Yaeger R, Desai J, Zhang X, Usari T, Mori A, Tabernero J. BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC). 2023 ASCO Annual Meeting 41(16), 2023. e-Pub 2023.
46. Morris VK, Yothers G, Kopetz S, Puhalla SL, Lucas PC, Iqbal A, Boland PM, Deming DA, Scott AJ, Lim HJ, Jacobs SA, Hong TS, Wolmark N, George TJ. Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study. 2024 ASCO Gastrointestinal Cancers Symposium 41(16), 2023. e-Pub 2023.
47. Johnson B, Haymaker C, Morris VK, Dasari A, Higbie VS, Shen JP, Parseghian C, Morelli MP, Huey R, Lee MS, Willis J, Raghav KP, Yuan Y, Zebala J, DePinho RA, Kopetz S, Overman M. A phase I/II trial of a CXCR1/2 inhibitor in combination with anti-PD-1 for circulating tumor DNA (ctDNA) positive & refractoryRAS-mutated microsatellite stable (MSS) colorectal cancer. AACR Annual Meeting 2023 83(8), 2023. e-Pub 2023.
48. Sorokin A, Marie PK, Gao F, Liu Z, Menter D, Kopetz S. A novel PDX-based 2-stage screening platform can identify active drug combinations against KRAS-mutated colorectal cancer. AACR Annual Meeting 2023 83(8), 2023. e-Pub 2023.
49. Jiang Y, Yu K, Montierth MD, Ji S, Shin SJ, Guo S, Cao S, Tang Y, Kopetz S, Msaouel P, Wang JR, Kimmel M, Loo PV, Zhu H, Wang W. Pan-cancer analysis of intra-tumor heterogeneity in 9,116 cancers using a novel regularized likelihood model. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
50. Lee HM, Sorokin A, Marie PK, Chowdhury S, Singh A, Anderson A, Alshenaifi JY, Meric-Bernstam F, Rai K, Kopetz S. Combining bromodomain and extraterminal (BET) protein inhibitor treatment with standard MAPK inhibitors improved MAPK signaling inhibition in colorectal cancer. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
51. Ding S, Marie PK, Zhang R, Bohn A, Moseley RM, Baro N, Brown D, Pittman K, Paduch M, Hsu D, Kopetz S, Shen X. Evaluating targeted therapy combination for refractory colorectal cancer using MicroOrganoSpheres (MOS). AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
52. Mohamed AM, Soeung M, Alshenaifi J, Fowlkes N, Manyam G, Davis J, Anderson A, Norton W, Deem AK, Gao S, Khanduri I, Bistow C, Carbone F, Napolitano S, Huang J, Maru DM, Menter DG, Draetta GF, Genovese G, Kopetz S. Recapitulating metastatic colorectal cancer in somatic mutation models for investigating the tumor immune microenvironment in minimal residual disease. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
53. Lee HM, Sorokin A, Marie PK, Chowdhury S, Singh A, Anderson A, Alshenaifi JY, Meric-Bernstam F, Rai K, Kopetz S. Combining bromodomain and extraterminal (BET) protein inhibitor treatment with standard MAPK inhibitors improved MAPK signaling inhibition in colorectal cancer. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
54. Guo S, Cheng X, Koval A, Ji S, Liang Q, Li Y, Owen LA, Kim IK, Weinstein J, Kopetz S, Shen JP, DeAngelis MM, Chen R, Wang W. Integration with benchmark data of paired bulk and single-cell RNA sequencing data substantially improves the accuracy of bulk tissue deconvolution. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
55. Rocha Lima CMSP, Yothers G, Puhalla SL, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Blanke CD, Jacobs SA, Hong TS, Wolmark N, Hochster HS, George TJ, Overman MJ. NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). 2023 ASCO Gastrointestinal Cancers Symposium 41(4), 2023. e-Pub 2023.
56. Kopetz S, Bekaii-Saab TS, Yoshino T, Chung C, Zhang X, Tabernero J. SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E–mutant microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
57. Barnett R, Gnerre S, Willis J, Overman MJ, Singh Raghav KP, Parseghian CM, Dasari A, Morelli MP, Johnson B, Eluri M, Drusbosky L, Kopetz S, Morris VK. ctDNA-based fusion detection for advanced colorectal cancer with a partner-agnostic assay. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
58. Janak A, Peacock O, White M, Guraieb-Trueba M, Nguyen ST, Alshenaifi J, Kopetz S, Johnson B, Smith GL, Chang GJ, You Y. Internet-based assessment tools for predicting colorectal cancer risk: How do they communicate individualized risk to the young adult?. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
59. Saeed A, Barnett R, Lou E, da Silva LM, Cho MT, Lieu CH, Fakih M, Kopetz S, Loree JM, Gholami S. A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
60. Ding S, Marie PK, Zhang R, Baro N, Brown DW, Bohn A, Pittman K, Paduch M, Hsu SD, Kopetz S, Shen X. Identifying targeted therapy combination for refractory colorectal cancer using micro-organospheres. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
61. Kopetz S, Yoshino T, Kim TW, Yaeger R, Desai J, Wasan HS, Cutsem EV, Maughan T, Eng C, Tie J, Elez E, Lonardi S, Zhang X, Chung C, Usari T, Nicholz T, Murphy DA, Tabernero J, Ciardiello F. BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
62. Kopetz S, Kasper S, Rivera F, Tournigand C, Cheng Y, Deshpande P, D'Alessio D, Angelozzi NA, da Silva ABP, Segal NH. Patient-reported outcomes (PROs) and biomarker assessments in daNIS-3, a phase II platform study of NIS793 (anti–TGF-β monoclonal antibody) and other investigational drug combinations with standard of care (SOC) vs SOC alone in patients (pts) with second-line metastatic colorectal cancer (mCRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
63. Kopetz S, Cutsem EV, Kuboki Y, Johnson B, Katakabe T, He M, Archuadze S, Shen L. A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
64. Morris VK, Guthrie KA, Kopetz S, Breakstone R, Karasic TB, Hu ZI, Bellasea S, Fakih M, Gholami S, Gold PJ, Philip PA. Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
65. Uppal A, White M, Chang GJ, Zeineddine FA, Zeineddine MA, Yousef AM, Scally C, Fournier KF, Newhook TE, You Y, Willis J, Kopetz S, YC Shen JP. Tumor mutations associated with outcomes in colorectal peritoneal metastases. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
66. Singh Raghav KP, Guthrie KA, Kopetz S, Tan BR, Denlinger CS, Fakih M, Overman MJ, Dasari A, Corum LR, Hicks LG, Patel M, Esparaz BT, Ali Kazmi SM, Alluri N, Colby S, Gholami S, Gold PJ, Chiorean E, Hochster HS, Philip PA. A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
67. Salem ME, Kopetz S, Tabernero J, Sinicrope FA, Chalabi M, Tie J, Kadakia KC, George TJ, Mauer E, Macera L, Chao CY, Lonardi S, Cutsem EV, Andre T, Overman MJ. Comprehensive characterization of KRAS mutations and inter-relation with primary tumor location in colorectal cancers. J Clin Oncol 41(suppl 4), 2023. e-Pub 2023.
68. Lieu CH, Lin Y, Kopetz S, Jacobs SA, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree JM, Wolmark N, Yothers G, George TJ, Dasari A. NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
69. Cohen SA, Kasi PM, Aushev VN, Hanna DL, Botta GP, Sharif S, Georgios I Laliotis MD, PhD, Sharma VR, Alqahtani A, Chandana SR, Kang S, Chakrabarti S, Somer BG, Kasi A, Dayyani F, Malla M, Jurdi AA, Liu MC, Aleshin A, Kopetz S. Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
70. Hecht J, Kopetz S, Welling T, Morelli MP, Molina JR, Kirtane K, Oberstein PE, Greenwald DR, Lin Y, Mardiros A, Beutner K, Lozac'hmeur A, Salahudeen A, Liechty KB, Vong J, Ng EW, Maloney DG, Go WY, Welch JS, Simeone DM. Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
71. Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz ES, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
72. Lenz H, Koessler T, Oberstein P, Cutsem EV, Kim S, Fritsch R, Prenen H, Morse M, Gani D, Derouazi M, Bogenrieder T, Kopetz S. KISIMA-01: A first-in-human trial of the heterologous prime-boost vaccine ATP128/VSV-GP128 with ezabenlimab (BI 754091) in patients with stage IV colorectal cancer. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
73. Nunez SK, Young CD, Griffen TL, Kopetz S, Lillard JW. Co-expressed gene networks in CRC CMS1 subtype. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
74. Lee HM, Napolitano S, Sorokin A, Woods MN, Chowdhury S, Alshenaifi JY, Singh AK, Shen JP, Meric-Bernstam F, Rai K, Kopetz S. Bromodomain and extraterminal (BET) protein inhibition sensitize BRAFV600E colorectal cancer to standard targeted therapies. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
75. Lenz H, Prenen H, Cutsem EV, Kössler T, Mayol J, Trapani F, Tihy M, Rubbia-Brandt L, Toso C, Bogenrieder T, Belnoue E, Derouazi M, Kopetz S. ATP128 vaccine with ezabenlimab promotes antigen-specific immune responses in stage IV colorectal cancer in the KISIMA-01 phase 1b trial. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
76. Korkut A, Li X, Kong E, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar J, Luna A, Menter D, Pilié P, Yap T, Kopetz S, Sander C. Precision combination therapies based on recurrent oncogenic co-alterations. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
77. Gopalan A, Gallup TD, Wood S, Maldonado J, Margain C, Esnaola NF, Kim MP, Kopetz E, Yun K. A novel 3D culture platform for precision medicine. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
78. Gouda MA, Duose DY, Lapin M, Zalles S, Huang HJ, Xi Y, Zheng X, Aldesoky AI, Alhanafy AM, Shehata MA, Wang J, Kopetz S, Meric-Bernstam F, Wistuba II, Luthra R, Janku F. Mutation-agnostic detection of colorectal cancer-specific cell-free DNA using targeted methylation sequencing. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
79. Minussi DC, Wang J, Schalck A, Yan Y, Wu H, Peng C, Hu M, Sei E, Edgerton M, Chen H, Contreras A, Hui D, Damodaran S, Kopetz S, Lim B, Navin N. Resolving clonal substructure from single cell genomic data in primary and metastatic tumors using CopyKit. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
80. Chowdhury S, Gupta R, Haridas V, Zeineddine MA, Kopetz S, Shen JP. Consensus molecular subtypes (CMS) of colorectal cancer predict anti-EGFR response irrespective of tumor sidedness. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
81. Waizenegger IC, Lu H, Thamer C, Savarese F, Gerlach D, Rudolph D, Vellano CP, Marotti M, Heymach J, Kopetz S, Heffernan TP, Marszalek JR, Petronczki MP, Hofmann MH, Kraut N. Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
82. Negrao MV, Morelli MP, Jazaeri AA, Johnson B, Kebriaei P, Deninger D, Groot ED, Collinson-Pautz MR, Demars NA, Holland JS, Heymach J, Baffa R, Kopetz S. First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
83. Kopetz S. ctDNA as a Tool to Detect Minimal Residual Disease After Surgery, 2022. e-Pub 2022.
84. Hecht J, Kopetz S, Patel SP, Welling T, Morelli MP, Borad MJ, Molina JR, Kirtane K, Lin Y, Fan-Port M, Mardiros A, Beutner K, Lozac'hmeur A, Lau D, Liechty KB, Vong J, Ng E, Maloney DG, Go WY, Simeone DM. Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
85. Simeone DM, Hecht J, Patel SP, Morelli MP, Kirtane K, Borad MJ, Maus MV, Sunwoo JB, Welling T, Lin Y, Garon EB, Kopetz S, Locke FL, Liechty KB, Lozac'hmeur A, Beutner K, Ng EW, Go WY, Maloney DG, Molina JR. BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
86. Villarreal O, Zeineddine FA, Chacko R, Parseghian CM, Johnson B, Willis J, Lee MS, Morris VK, Dasari A, Singh Raghav KP, Overman MJ, You Y, Wang Y, Maru DM, YC Shen JP, Kopetz S. Outcomes of IBD-associated colorectal cancer and implications in early-onset colorectal cancer. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
87. Woods MN, Falco VD, Prisco C, Martini G, Guerrera LP, Belli V, Troiani T, Morris VK, YC Shen JP, Lee HM, Villarreal O, Sorokin A, Marie PK, Ciardiello F, Kopetz S, Napolitano S. Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
88. Rocha Lima CMSP, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Blanke CD, Hong TS, Wolmark N, Hochster HS, George TJ, Overman MJ. Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
89. Amaria RN, Vining DJ, Kopetz S, Overman MJ, Javle MM, Antonoff M, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel KM, Wilson L, Fellman BM, Haymaker CL, Yuan Y, Forget M, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous expanded tumor infiltrating lymphocytes (TILs) in multiple solid tumors. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
90. Johnson B, Yang D, Dada HI, Morris VK, Wang X, Dasari A, Singh Raghav KP, Kee BK, YC Shen JP, Huey R, Lee MS, Parseghian CM, Le P, Morelli MP, Willis J, Wolff RA, Drusbosky L, Overman MJ, Kopetz S. RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
91. Morris VK, Parseghian CM, Escano M, Johnson B, Singh Raghav KP, Dasari A, Huey R, Overman MJ, Willis J, Lee MS, Wolff RA, Kee BK, Le P, Margain C, Gallup D, Tam A, Foo WC, Xiao L, Yun K, Kopetz S. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
92. Loree JM, Topham JT, Kennecke HF, Feilotter H, Lee YS, Virk S, Kopetz S, Duose DY, Manyam GC, Morris JS, Maru DM, Renouf D, Jonker DJ, Tu D, O'Callaghan CJ, Chen EX. Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC). J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
93. Parseghian CM, Sun R, Woods MN, Napolitano S, Alshenaifi J, Willis J, Nunez SK, Sorokin A, Marie PK, Singh Raghav KP, Morris VK, YC Shen JP, Sanchez EV, Rehn M, Ang A, Troiani T, Kopetz S. Resistance mechanisms to anti-EGFR therapy in RAS/RAF wildtype colorectal cancer varies by regimen and line of therapy. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
94. Dasari A, Abdelrahim M, Acoba JD, Alluri KC, Dragovich T, Ali Kazmi SM, Musher BL, Sun R, Wong L, You Y, Zaiden RA, Kopetz S. Minimal residual disease assessment in colorectal cancer (MiRDA-C). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
95. Parseghian CM, Sanchez EV, Sun R, Eluri M, Morris VK, Johnson B, Morelli MP, Overman MJ, Willis J, Huey R, Singh Raghav KP, Dasari A, Kee BK, Wolff RA, YC Shen JP, Kopetz S. Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. J Clin Oncol 40(suppl. 16), 2022. e-Pub 2022.
96. Bent AH, Maru DM, Vauthey J, Dasari A, Johnson B, Kee BK, Parseghian CM, Menter D, Overman MJ, Morris VK, Fan P, Koyama K, Maeda N, Kopetz S, Singh Raghav KP. HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
97. Lee MS, Zemla TJ, Ciombor KK, McRee AJ, Akce M, Dakhil SR, Jaszewski BL, Ou F, Bekaii-Saab TS, Kopetz S. A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
98. Simmons K, Kee BK, Singh Raghav KP, Johnson B, Kopetz S, Willis J, Dasari A, Sanchez EV, Ludford K, Parseghian CM, Lee MS, Le P, YC Shen JP, Overman MJ, Morris VK. Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
99. Bhamidipati D, Singh Raghav KP, Morris VK, Kopetz S, Kee BK, Johnson B, Willis J, Dasari A, Morelli MP, Parseghian CM, Lee MS, Le P, YC Shen JP, Ludford K, Overman MJ. Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl), 2022. e-Pub 2022.
100. Dasari A, Lin Y, Kopetz S, Jacobs SA, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Wolmark N, Yothers G, George TJ, Lieu CH. Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008. J Clin Onco 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
101. Nusrat M, Syed MA, Katkhuda R, Parra ER, Wistuba II, Kong P, Koehne A, Dasari A, Overman MJ, Menter D, Kopetz S. The immune impact of PI3K-AKT pathway inhibition in colorectal cancer. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
102. Salem ME, Andre T, El-Refai SM, Kopetz S, Tabernero J, Sinicrope FA, Tie J, George TJ, VanCutsem E, Mauer E, Lonardi S, Overman MJ, Foureau D. Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC). J Clin Onco 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
103. Salem ME, Kopetz S, El-Refai SM, Tabernero J, Sinicrope FA, Tie J, George TJ, VanCutsem E, Mauer E, Lonardi S, Andre T, Overman MJ, Foureau D. Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E-mutated versus MSI-H BRAF wild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immunometabolomic biomarkers. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
104. Naing A, Mamdani H, Barve MA, Johnson ML, Morgensztern D, Olszanski AJ, Wolff RA, Pant S, Chaney MF, Adebanjo T, Fan J, Kim RD, Kopetz S. Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study. J Clin Onco 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
105. Singh Raghav KP, Ou F, Venook AP, Innocenti F, Sun R, Lenz H, Kopetz S. Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
106. Johnson B, Yang D, Dada HI, Drusbosky L, Kopetz S. Comprehensive landscape of BRAF variant classes, clonalities, and comutations in metastatic colorectal cancer using ctDNA profiling. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
107. Johnson B, Kopetz S, Hwang H, Yuan Y, DePinho RA, Zebala J, Overman MJ. STOPTRAFFIC-1: A phase I/II trial of SX-682 in combination with nivolumab for refractory RAS-mutated microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
108. Kopetz S, Grothey A, Yaeger R, Ciardiello F, Desai J, Kim TW, Maughan T, Cutsem EV, Wasan HS, Yoshino T, Edwards ML, Golden A, Gollerkeri A, Tabernero J. BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
109. Kopetz S, Yoshino T, Kim TW, Desai J, Yaeger R, Cutsem EV, Ciardiello F, Wasan HS, Maughan T, Zhang Y, Usari T, Chung C, Zhang X, Tabernero J. BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
110. Kopetz S, Murphy DA, Pu J, Yaeger R, Ciardiello F, Desai J, Cutsem EV, Wasan HS, Yoshino T, Elez E, Golden A, Zhu Z, Zhang X, Tabernero J. Evaluation of baseline BRAF V600E mutation in circulating tumor DNA and efficacy response from the BEACON study. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
111. Kopetz S, Morris VK, Alonso-Orduña V, Garcia-Alfonso P, Reboredo M, Montes AF, Maurel J, Paez D, Reinacher-Schick AC, Höhler T, Carrasco J, Galligan BM, Manning L, Preußner L, Tureci Ö, Sahin U. A phase 2 multicenter, open-label, randomized, controlled trial in patients with stage II/III colorectal cancer who are ctDNA positive following resection to compare efficacy of autogene cevumeran versus watchful waiting. J Clin Onco 2022 ASCO Annual Meeting 40(supply 16), 2022. e-Pub 2022.
112. Kopetz S, Morris VK, O'Neil B, Bridgewater JA, Graham J, Parkes EE, Saunders MP, Asken E, Goodwin L, Phillips C, Robertson J, Tilston C, Woodcock S, Cook N. A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
113. Kopetz S, Bekaii-Saab TS, Yoshino T, Chung C, Zhang X, Tabernero J. SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
114. Li F, White MG, Davis J, Hoffman KL, Menter D, Ajami N, Zhang X, Morris JS, Jenq RR, Petrosino J, Wargo JA, Kopetz S, Daniel CR. Tumor microbiota profiles are associated with molecular subtype and survival in colorectal cancer patients. Cancer Res 2021 American Association for Cancer Research 81(suppl 13), 2021. e-Pub 2021.
115. Zhang X, Hoffman KL, Li F, Irajizad E, Browman G, Basen-Engquist K, Hanash S, Scheet P, Okhuysen PC, Kopetz S, Petrosino J, Daniel CR. Beans to Enrich the Gut microbiome vs. Obesity's Negative Effects: First results from the BE GONE Trial in high-risk colorectal patients. Cancer Res 2021 American Association for Cancer Research 81(suppl 13), 2021. e-Pub 2021.
116. Coker O, Sorokin A, Gale K, Gao F, Shen JP, Kwong L, Wu J, Lee HM, Woods M, Villareal O, Kopetz S. Oncogenic KRASG12C dependency in colorectal cancer. Cancer Res 2021 American Association for Cancer Research 81(suppl 13), 2021. e-Pub 2021.
117. Kopetz S, Grothey A, Ciardiello F, Desai J, Kim TW, Maughan T, Cutsem EV, Wasan HS, Yaeger R, Yoshino T, Gollerkeri A, Edwards M, Lizaso MR, Tabernero J. Global BRAF testing practices in metastatic colorectal cancer. J Clin Oncol 2021 Gastrointestinal Cancers Symposium 39(3_suppl), 2021. e-Pub 2021.
118. A GrotheyKopetz S, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, Yoshino T, Maharry K, Christy-Bittel J, Gollerkeri A, Tabernero J. Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC. Annals of Oncology 31(S3):S243, 2020. e-Pub 2020.
119. Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Gollerkeri A, Maharry K, Loupakis F, Hong Y, Steeghs N, Guren T, Arkenau H, Garcıa Alfonso P, Sandor V, Christy-Bittel J, Anderson L, Tabernero J. BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. Annals of Oncology 30(Suppl 4):iv154, 2019. e-Pub 2019.
120. Kopetz S, Grothey A, Yaeger R, Cuyle PA, Huijberts S, M Schellens JH, Elez E, Fakih M, Viladot CM, Peeters M, Desai J, Yoshino T, Ciardiello F, Wasan HS, Maharry K, Christy-Bittel J, Gollerkeri A, Cutsem EV, Tabernero J. Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC). J Clin Oncol 37(suppl 4; abstr 688), 2019. e-Pub 2019.
121. Kopetz S, Spira AI, Wertheim M, Kim E, Tan BR, Lenz HJ, Nikolinakos P, Rich P, Smith DA, Helwig C, Dussault I, Ojalvo L, Gulley JL. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
122. Kopetz S, Spira, AI, Wertheim M, Kim E, Tan BR, Lenz HJ. A bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial. Journal of Clinical Oncology 36(4suppl):764, 2018. e-Pub 2018.
123. Kopetz S, Zagonel V, Overman MJ, McDermott R, Morse MA, Chen FL, Lee J, Moss RA, Ling L, Greenfield A, Greenawalt D, Cao ZA. Microbiome Analyses in Patients with Previously Treated, Deficient DNA Mismatch Repair/Microsatellite Instability-High Metastatic Colorectal Cancer Treated with Nivolumab +/- Ipilimumab: CheckMate 142, Bristol Myers Squibb, 2017. e-Pub 2017.
124. Kopetz S, Lonardi S, McDermott RS, Aglietta M, Hendlisz A, Morse M, Leach JW, Neyns B, Chan E, Chen F, Wong KYM, Lee JJ, Garcia-Alfonso P, Hill AG, Lenz HJ, Desai J, Moss RA, Cao ZA, Overman MJ, Andre T. Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study. J Clin Oncol 35(suppl), 2017. e-Pub 2017.
125. Kopetz S, McDonough SL, Morris II VK, Lenz HJ, Magliocco AM, Atreya CE, Diaz Jr LA, Joseph Allegra C, Wang SE, Hanyoung Lieu C, Eckhardt SG, Semrad TJ, Kaberle K, Guthrie KA, Hochster HS. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). 2017 Gastrointestinal Cancers Symposium 35(suppl), 2017. e-Pub 2017.
126. Kopetz S. Opportunities for integration of PDX models into clinical trials, 2016. e-Pub 2016.
127. Kopetz S, McDonough S, Morris VK, Lenz HJ, Magliocco AM, Atreya CE, Diaz LA, Allegra CJ, Lieu CH, Eckhardt SG, Semrad TJ, Kaberle K, Guthrie K, Hochster HS. S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC). J Clin Oncol 33(suppl 3), 2015. e-Pub 2015.
128. Kopetz S, Litzenburger B, Kinyua W, Sajan B, Subbiah V, Zinner R, Wheler JJ, Hong DS, Tsimberidou AM, Overman MJ, Pagliaro LC, Busaidy NL, Westin SN, Glisson BS, Heymach J, Meric-Bernstam F, Shaw KR, Lee JJ, Broaddus R. Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
129. Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR, Dasari A, Raghav KPS, Vilar Sanchez E, Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, Luthra R, Routbort M, DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC) 32(5s), 2014. e-Pub 2014.
130. Kopetz S, Jiang Z, Overman MJ, Dreezen C, Tian S, Li Y, Simon I, Chang GJ, Maru DM. Genomic classifiers (ColoPrint/MSI-Print) predict outcome and chemotherapy benefit in stage II and III colon cancer patients. J Clin Oncol 31(suppl 4), 2013. e-Pub 2013.
131. Kopetz S, Jiang Z, Overman MJ, Rosenberg R, Salazar R, Tabernero J, Stork L, Li Y, Simon I, Chang GJ, Maru DM. Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients. J Clin Oncol 31(suppl), 2013. e-Pub 2013.
132. Kopetz S, Tran HT, Cunningham D, Mookerjee B, Pike L, Jurgensmeier J, Heymach J. Association of circulating cytokine and angiogenic factors (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer. J Clin Oncol 29((suppl 4; abstr 406)), 2011. e-Pub 2011.
133. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, Nolop KB, Bhattacharya S, Saltz L. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors, 2010. e-Pub 2010.
134. Kopetz S, Hoff P, Eng C, Overman MJ, Glover KY, Chang DZ, Wolff RA, Abbruzzese JL, Ellis LM, Heymach JV. Levels of angiogenic cytokines prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab:292, 2009. e-Pub 2009.
135. Kopetz S, Wolff R, Eng C, Henry L, Glover K, Chang D, Overman M, Gallick G, Abbruzzese J. Phase IB study of Src inhibitation with dasatinib in combination with 5-fluorouracil, leuvocorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer:LB-69, 2008. e-Pub 2008.
136. Kopetz S, Mita MM, Sankhala KK, Moseley J, Sherman BM, Bradley CR, Tolcher AW. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors, 2008. e-Pub 2008.
137. Kopetz S, Shah AN, Gallick GE. Src Continues Aging: Current and Future Clinical Directions:7232, 2007. e-Pub 2007.
138. Kopetz S, Wu J, Davies M, Johnson F, Donato N. Synergistic effects of combination therapy with anti-EGFR and anti-Src therapy in vitro in colon cancer, 2007. e-Pub 2007.
139. Kopetz S. Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer, 2007. e-Pub 2007.
140. Kopetz S, Wu J, Davies M, Parikh N, Johnson F, Gallick G, Donato N. Synergistic activity of Src and EGFR inhibitors in colon cancer, 2007. e-Pub 2007.
141. Kopetz S, Wu J, Johnson F, Donato N. Anti-tumor effects of combination therapy with anti-EGFR and anti-Src therapy in colorectal cancer:B51, 2006. e-Pub 2006.
142. Kopetz S, Dang J, Overman M, Phan L, Feig B, Patel D, Wolff RA, Eng CA, Abbruzzese JL, Hoff P. Bevacizumab toxicity and efficacy are unaffected by regimen or resection status: A single institution retrospective study, 2006. e-Pub 2006.
143. Osterlund E, Maddalena G, Pellatt AJ, Eluri M, Parseghian C, Aziz K, Alfaro K, Kell RJ, Manyam GC, Konishi T, Overman MJ, Morelli MP, Willis J, YC Shen JP, Singh Raghav KP, Newhook TE, Dasari A, Maitra A, Van K Morris II, Kopetz S. Biologic correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study. 2025 ASCO Annual Meeting 43(16).
144. Elez E, Yoshino T, Shen L, Lonardi S, Cutsem EV, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Van K Morris II, Wu C, Usari T, Laliberte RJ, Dychter SS, Zhang X, Tabernero J, Kopetz S. First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer. 2025 ASCO Annual Meeting 43(17).
145. Kopetz S, Garcia-Carbonero R, Han S, Rivera II, Rodriguez JC, Boni V, Vieito M, Miguel MJ, Pallis AG, Habermehl C, Siddiqui A, Kato K. Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer: updated clinical data from the Phase 1 PROCEADE-CRC-01 study. 2025 ESMO Congress 36(2).
146. Osterlund E, Maddalena G, Pellatt AJ, Vetere G, Eluri M, Parseghian C, Aziz KE, Alfaro K, Kell RJ, Konishi T, Overman MJ, Morelli MP, Willis J, Shen J, Raghav K, Newhook T, Shen X, Morris V, Dasari NA, Kopetz S. Circulating tumor DNA (ctDNA) clearance and correlation with outcome in the INTERCEPT colorectal cancer (CRC) study. 2025 ESMO Congress 36(2).
147. Overman MJ, Vetere G, Savchenko M, Shubin A, Vinocha A, Shah P, Kruglikov R, Chowdhury S, Dudakov A, Yudina A, Higbie V, Tarasov A, Tarabarova A, Haldar S, Zaitsev A, Van K Morris II, YC Shen JP, Goldberg MI, Kopetz S, Bagaev A. Circulating free RNA (cfRNA) as a predictive tool for immunotherapy benefit in mismatch-repair-deficient colorectal cancer (dMMR CRC). 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
148. Morelli MP, Basar R, Marin D, Zeller BE, Willis J, Kee BK, Jacob S, Diao S, Huey RW, Van K Morris II, Bent AH, Haldar S, Nurmammadova A, Bohat R, Menter D, Overman MJ, Shen X, Kopetz S, Shpall EJ, Rezvan K. Phase 1 dose escalation and expansion study of TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells in combination with cetuximab in patients with colorectal cancer (CRC) with minimal residual disease (MRD). 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
149. Gist G, Haddad A, Lewis KA, Konishi T, Chang GJ, White M, Messick C, Peacock O, Tzeng CD, Tran Cao HS, Smith JJ, Kopetz S, Parseghian C, Dasari A, Van K Morris II, Vauthey J, You Y, Newhook TE, Bhutian N. Managing the primary tumor in patients with rectal cancer and synchronous liver metastases: The role of organ preservation. 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
150. Payapwattanawong S, Osterlund E, Vetere G, Bent AH, Dasari A, Kee BK, Parseghian C, Willis J, YC Shen JP, Singh Raghav KP, Eluri M, Morelli MP, Overman MJ, Le P, Huey RW, Martinez SA, Higbie V, Shen X, Van K Morris II, Kopetz S. Aspirin use and PI3K mutations in metastatic colorectal cancer (mCRC). 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
151. Vetere G, Cautino SC, Yousef MM, Payapwattanawong S, Agrawal N, Roy P, Abraham S, Alfaro K, Maddalena G, Alshenaifi JY, Parseghian C, Van K Morris II, Singh Raghav KP, Willis J, Overman MJ, Dasari A, YC Shen JP, Shen X, Kopetz S, Osterlund E. Mode of presentation and symptoms of colorectal cancer (CRC) by primary tumor and molecular subgroup: A large-scale AI-powered analysis. 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
152. Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman T, Cole SW, Zuckerman DS, Hong TS, Henry NL, Ganz PA, Blanke CD, Wolmark N, Overman MJ. Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)— NRG-GI004/SWOG-S1610. 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
153. Bof F, Maddalena G, Van K Morris II, Parseghian C, Higbie V, Eluri M, Morelli MP, YC Shen JP, Huey RW, Willis J, Kee BK, Haldar S, Martinez SA, Lonardi S, Bergamo F, Singh Raghav KP, Dasari A, Overman MJ, Kopetz S, Bent AH. Cracking the code: Clinical predictors of brain metastases in colorectal cancer. 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
154. Eng C, Kopetz S, Tabernero J, Elez E, Yoshino T, Cutsem EV, Wasan HS, Van K Morris II, Usari T, Shah K, Rezai N, Zhang X, Tie J. BREAKWATER phase 3: Post hoc subgroup analyses by age in patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
155. Vetere G, Osterlund E, Yousef MM, Payapwattanawong S, Maddalena G, Alshenaifi JY, Alfaro K, Knafl M, Van K Morris II, Parseghian C, Wolff RA, Dasari A, Overman MJ, Kopetz S, YC Shen JP. Overall survival of immunotherapy versus standard of care in microsatellite stable metastatic colorectal. 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
156. Boursi B, Stemmer A, Chapin WJ, Shacham-Shmueli E, Kopetz S, Andre T, Overman MJ, Pietrantonio F, Margalit O. Durable responses to immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status. 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
157. Eng C, Kopetz S, Tabernero J, Elez E, Yoshino T, Cutsem EV, Wasan HS, Van K Morris II, Usari T, Shah K, Rezai N, Zhang X, Tie J. BREAKWATER phase 3: Post hoc subgroup analyses by age in patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC). 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
158. Vetere G, Osterlund E, Yousef MM, Payapwattanawong S, Maddalena G, Alshenaifi JY, Alfaro K, Knafl M, Van K Morris II, Parseghian C, Wolff RA, Dasari A, Overman MJ, Kopetz S, YC Shen JP. Overall survival of immunotherapy versus standard of care in microsatellite stable metastatic colorectal cancer: A propensity score matched analysis of 708 patients. 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
159. Kopetz S, Tabernero J, Lonardi S, Shen L, Wasan HS, Yoshino T, Cutsem EV, Kim TW, Eng C, Ciardiello F, Desai J, Maughan T, Yaeger R, Usari T, Zhang X, Beyzarov E, Mori A, Whalley E, Zhang X, Elez E. BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC). American Society of Clinical Oncology.
160. Kopetz S, Shah KN, Yoshino T, Yaeger R, Eng C, Cutsem E, Wasan HS, Desai J, Ciardiello F, Maughan TS, Kim TW, Fernandez E, Tie J, Takiya L, Rosenthal S, Saul M, Hamilton P, Whalley E, Zhang X, Tabernero J. 7R0 Molecular correlates of enhanced outcome with first-line (1L) encorafenib + cetuximab (EC) ± mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BREAKWATER study. ESMO Gastrointestinal Cancers Congress 2026.
161. Bent AH, Parseghian C, Van K Morris II, Higbie V, Eluri M, Kee BK, Huey RW, Willis J, Morelli MP, Haldar S, Martinez SA, YC Shen JP, Singh Raghav KP, Overman MJ, Horodecky K, Alfaro K, Aziz K, Kell RJ, Kopetz S, Dasari A. A phase 2 trial of TAS-102 with or without celecoxib in ctDNA-defined minimal residual disease (MRD) in colorectal cancer after completion of adjuvant chemotherapy. 2026 ASCO Gastrointestinal Cancers Symposium 44(2).
162. Yaeger R, Uboha NV, Klempner SJ, Bekaii-Saab TS, Sabari JK, Barve MA, Saltzman JN, Peguero JA, Paulson AS, Jänne PA, Pelster M, Cruz-Correa M, Kim AMK, Hu N, Ahmad HA, Kopetz S. Adagrasib (Ada) + cetuximab (Cetux) for KRASG12C-mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
163. Overman MJ, Yothers G, Puhalla SL, Sanoff HK, Cohen DJ, Guthrie KA, Ganz PA, Kopetz S, Lucas PC, Blanke CD, Jacobs SA, Hong TS, Wolmark N, Hochster HS, George TJ, Lima CM. Colorectal cancer metastatic dMMR immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer 9NRG-GI004/SWOG-S1610). 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
164. Arrondo E, Iida N, Hashimoto T, Ozaki H, Shibuki T, Imai M, Fujisawa T, Nakamura Y, Bando H, Kopetz S, Shen JP, Yoshino T. Molecular characteristics and prognostic impact of GNAS mutations in colorectal cancer: An international collaborative study between United States and Japan. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
165. Li H, Kopetz S, Yin Y, Peng J, Keenan H. A real-world study of treatment patterns among patients (pts) with metastatic colorectal cancer (mCRC) receiving third-line (3L) or fourth-line (4L) treatment in the US. 2025 ASCO Gastrointestinal Cancers Symposium 43(64).
166. Shah PK, Aushev VN, Ensor J, Sanchez SA, Wang CG, Cannon TL, Berim LD, Feinstein T, Grothey A, McCollom JW, Kalmadi SR, Zakari A, Dayyani F, Gravenor D, Liu MC, Jurdi AA, Aleshin A, Meyer JM, Sharif S, Kopetz S. Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
167. Yousef MM, Yousef AM, Alfaro K, Maddalena G, Fanaeian MM, Knafl M, Roy P, Vetere G, Bhutiani N, Goldstein D, Uppal A, White M, Fournier KF, Helmink BA, Singh Raghav KP, Dasari A, Overman MJ, Zhao D, Kopetz S, YC Shen JP. Utilizing an automated, high-throughput platform to generate comprehensive clinical & molecular datasets to enable a real-world evidence approach for improving care of patients with gastrointestinal malignancies. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
168. Pan K, Baig Y, Willis J, Dasari A, Bent AH, Higbie V, Huey RW, Kee BK, Lee MS, Parseghian C, Morelli MP, Shen JP, Kopetz S, Morris VK. Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
169. Morelli MP, Basar R, Marin D, Huey RW, Banerjee PP, Willis J, Morris VK, Rafei H, Dasari A, Kee BK, Zeller BE, Diao S, Menter D, Shpall EJ, Kopetz S, Rezvani K. A phase Ib study of immunotherapy with ex-vivo pre-activated and expanded CBNK cells in combination with cetuximab, in patients with colorectal cancer (CRC) with minimal residual disease (MRD): Final report. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
170. LaPelusa MB, Qiao W, Iorgulescu B, Lucas FAS, Patel K, Bhamidipati D, Thomas JV, You YN, Foo WC, Maru DM, Thirumurthi S, Morris VK, Kopetz S, Overman MJ, Ludford K. Prognostic value of circulating tumor DNA for progression-free survival in patients with locally advanced dMMR/MSI-H colorectal cancer managed without surgery. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
171. Lieu CH, Yu G, Kopetz S, Puhalla SL, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree JM, Wolmark N, Yothers G, George TJ, Dasari A. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America). 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
172. Bhutiani N, Chiang YJ, Uppal A, Konishi T, White M, Vauthey JN, Kopetz S, Overman MJ, Chang GJ, Tran Cao H. Patterns of metastatic spread and survival outcomes for stage IV left-sided colon vs. rectal cancers: A real-world analysis. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
173. Morris V, Quintanilha J, Elvin J, Graf R, Kopetz S. Clinical relevance of tumor fraction assessment from circulating tumor DNA in metastatic colorectal cancer. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
174. Higbie V, LaPelusa MB, Shah P, Childress M, Gasco A, An A, Bent AH, Kee BK, Kopetz S, Le P, Morris VK, Pant S, Parseghian C, Shen JP, Wolff RA, Overman MJ. Serial monitoring of circulating tumor DNA as a marker of response to immune checkpoint blockade in MSI-H gastrointestinal tumors. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
175. Pant S, Smaglo BG, Huey RW, Haldar SD, Morelli MP, Willis J, Xiao L, Yuan Y, Attanasio S, Shah R, Citron F, Zhao D, Kopetz S, Maitra A, Welsch D, Sheth R, Bhosale P, Wolff RA, Viale A. A phase 1b dose escalation trial of gemcitabine and nab-paclitaxel in combination with lixumistat in patients with advanced pancreatic cancer. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
176. Maddalena G, Perissinotto E, Intini R, Morris V, Bergamo F, Newhook T, Lonardi S, Kopetz S. Challenges in patient selection for surgical options in V600E BRAF–mutated metastatic colorectal cancer. 2025 ASCO Gastrointestinal Cancers Symposium.
177. Dasari A, Mazard T, Cohen R, Elez E, Tarazona N, Borg C, Rinaudo P, Chêne L, Fagerberg J, Schmoll HJ, Cervantes A, Tabernero J, Kopetz S. Survival of patients (pts) with microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal carcinoma (mCRC) treated with EO4010 + nivolumab (EO/N). 2025 ASCO Annual Meeting 43(16).
178. Vinocha A, Dasari A, Li JJ, Thomas JV, Kopetz S, Hu ZI, Shen JP, Raghav KP, Overman MJ. Brain metastasis in patients with primary gastrointestinal malignancy on anti-HER2 therapy. 2025 ASCO Annual Meeting 43(16).
179. Dasari A, Yu G, Kopetz S, Puhalla SL, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree JM, Wolmark N, Yothers G, George TJ, Lieu CH. Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008. 2025 ASCO Annual Meeting 43(16).
180. Bent AH, Parseghian C, Morris VK, Kee BK, Huey RW, Morelli MP, Shen JP, Jernigan K, Fernandez A, Harrison C, Horodecky K, Dasari A, Alfaro K, Aziz K, Kell RJ, Kopetz S. DAILY: A prospective single arm study evaluating the impact of vitamin D, aspirin, exercise, and diet in colorectal cancer patients with ctDNA-defined minimal residual disease. 2025 ASCO Annual Meeting 43(16).
181. Xavier CB, Kang L, Le H, Kahle M, Tsimberidou MA, Naing A, Dumbrava EE, Ahnert JR, Pohlmann PR, Piha-Paul SA, Fu S, Champiat S, Yap TA, Tang TY, Kopetz S, Meric-Bernstam F, Hong DS. Colorectal cancer with gene fusions: Navigating the genomic landscape and treatment selection in a phase I unit. 2025 ASCO Annual Meeting 43(16).
182. Lim AM, Lin K, Abdelfattah N, Parseghian C, Morelli MP, Willis J, Huey RW, Higbie V, Bent AH, Eluri M, Kee BK, Wolff RA, Singh Raghav KP, Dasari A, Overman MJ, YC Shen JP, Kopetz S, Van K Morris II. Clinicopathologic features of complement activation signatures in colorectal cancer. 2025 ASCO Annual Meeting 43(16).
183. Vetere G, Sun R, Van K Morris II, Dasari A, Kee BK, YC Shen JP, Willis J, Morelli MP, Sorokin A, Marie PK, Wolff RA, Overman MJ, Singh Raghav KP, Sanchez EV, Huey RW, Higbie V, Le P, Baig Y, Kopetz S, Parseghian C. Open-label phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC). 2025 ASCO Annual Meeting 43(16).
184. Amaria R, Kopetz S, Morelli M, Blumenschein G, Altan M, Sanber K, Jazaeri A, Davies M, Diab A, Glitza I, McQuade J, Ikeguchi A, Tawbi H, Bernatchez C, Forget M, Haymaker C, Wong K, Tobin E, Benson M, Truppel-Hartmann A. A phase 1/2 study of KSQ-004EX: Autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and Regnase-1, in patients with select advanced solid tumors. 2025 ASCO Annual Meeting 43(16).
185. Kopetz S. Minimal Residual Disease Detection and Intervention: Challenges and Opportunities. 2024 ASCO Annual Meeting.

Book Chapters

1. Yu, IS, Advani, S, Kopetz, S. Initial Systemic Chemotherapy for Metastatic Colorectal Cancer, 279-286, 2022.
2. Dasari A, Johnson B, Parseghian C, Raghav K, Kopetz S. Colorectal Cancer. In: The MD Anderson Manual of Medical Oncology. 3rd, 2020.
3. Heymach JV, Zurita-Saavedra A, Kopetz S, Cascone T, Nilsson M. Tumor angiogenesis. In: Holland-Frei Cancer Medicine, 2017.
4. Hong DS, Kopetz ES, George GC. Colorectal Cancer (Adenocarcinoma). In: Handbook of Targeted Cancer Therapy. Wolters Kluwer Health, 2015.
5. Bhadkamkar N, Crane CH, Rodriguez-Bigas M, Kopetz S, Eng C. Colorectal Cancer. In: The MD Anderson Manual of Medical Oncology. 2nd, 2011.
6. Hoff PMG, Kopetz S. Systemic Therapy for Non-operable Colorectal Cancer Metastases. In: Liver Metastases. Springer, 51-8, 2008.
7. Kopetz S. Targeted Therapy in Cancer. In: Targeted Therapy for Colorectal Cancer. Humana Press, 101-24, 2008.
8. Kopetz S, Raber M, Abbruzzese J. Colorectal, Anal, and Unknown Primary Cancer (electronic web update). In: Cancer Medicine, 2006.
9. Kopetz S, Hoff P. Management Issues in Patients Presenting with Stage IV Colorectal Cancer. In: Advanced Therapy in Surgical Oncology. Decker Press, 281-91, 2006.

Letters to the Editor

1. Raghav K, Kopetz S, Yuan Y. Reply to Y. Yu et al. Journal of Clinical Oncology 41: 1495-1496, 2023.
2. Sun, H, Cao, S, Mashl, RJ, Mo, CK, Zaccaria, S, Wendl, MC, Davies, S, Bailey, MH, Primeau, T, Hoog, J, Mudd, JL, Dean, DA, Patidar, R, Chen, L, Wyczalkowski, MA, Jayasinghe, R, Rodrigues, FM, Terekhanova, NV, Li, Y, Lim, KH, Wang-Gillam, A, Van Tine, BA, Ma, C, Aft, R, Fuh, KC, Schwarz, JK, Roth, JA, Tapia, C, Yang, F, Akcakanat, A, Chen, H, Dai, B, Gibbons, DL, Ha, MJ, Jensen, VB, Kim, M, Kopetz, S, Menter, DG, Meraz, I, Sorokin, A, Wang, J, Westin, SN, Xi, Y, Yap, TA, Yennu Nanda, VG, Zhang, X, Zheng, X, Davies, MA, Fang, B, Meric-Bernstam, F. Author Correction. Nature communications 13, 2022.
3. Kopetz S, Abbruzzese JL. Hidden Biases in an Observational Study of Bevacizumab Beyond Progression. J Clin Oncol 27: 1732-3, 2009.